Treatment
Alectinib clinical trials
We’re tracking 20 recruiting studies that include Alectinib, each written for real people, not researchers, below.
Recruiting studies
- NCT05525338RecruitingPhase 4
Test standard vs adjusted alectinib dose using blood levels
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Villejuif, Val-de-MarneAges 18 years+ - NCT05713006RecruitingPhase 1/Phase 2
Alectinib drug handling study for ALK-positive advanced lung cancer
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
Mexico City, Mexico CityAges 18 years+ - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT06862869Recruiting
Alectinib after surgery for early ALK-positive lung cancer
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
Zhanjiang, GuangdongAges 18 years+ - NCT07001384RecruitingPhase 1
Alectinib and Duvelisib for ALK-positive anaplastic large cell lymphoma
This trial tests two oral targeted drugs—alectinib and duvelisib—for people whose ALK-positive anaplastic large cell lymphoma has come back or not responded after at least one prior chemotherapy. The goal is to see if this combination can help control the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Glendale, ArizonaAges 18 years+ - NCT04423185RecruitingPhase 2
Precision medicine trial for rare advanced solid tumors
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
BeijingAges 18 years+ - NCT07207278Recruiting
Genetics and immune study of lung signet ring cell cancer
This research study is looking at the unique genetic makeup and immune features of a rare type of lung cancer called signet ring cell carcinoma. By studying tumor samples and medical data, researchers hope to find better ways to understand and eventually treat this cancer.
Hangzhou, ZhejiangAges 18–85 - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Duarte, CaliforniaAges 18 years+ - NCT04322890RecruitingPhase 2
Study for advanced lung cancer with gene mutations
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Changsha, HunanAges 18 years+ - NCT04341181RecruitingPhase 2
Targeted cancer treatment chosen by tumor genetic test results
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
Aalborg, AalborgAges 18 years+ - NCT05159245RecruitingPhase 2
Targeted drug access for adults with advanced cancer
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
Turku, Southwest FinlandAges 18–100 - NCT05525858Recruiting
Genomic testing–guided treatment for advanced solid tumors
This study uses your tumor’s genetic test results to help match you to the most suitable treatment when standard options have failed or don’t exist. It may help by targeting therapies based on specific gene changes found in your cancer.
Bucheon-siAges 19 years+ - NCT05724004Recruiting
Alectinib then targeted radiation for ALK-positive lung cancer
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
StockholmAges 20 years+ - NCT05725200RecruitingPhase 2
Personalized treatment plan for metastatic colon or rectal cancer
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
OsloAges 18 years+ - NCT05987644RecruitingPhase 1/Phase 2
Timing of brain radiation for ALK-positive lung cancer with brain mets
This trial tests whether it is better to delay brain radiation or give it right away in people with ALK-positive lung cancer that has spread to the brain and is causing few or no symptoms. If you are starting alectinib, you may be able to join and help find the best timing for radiation.
Stanford, CaliforniaAges 18 years+ - NCT06532149Recruiting
Sexual health and erectile function in men with lung cancer
This study looks at how lung cancer and its treatments affect men's sexual health, including erectile function and hormone levels. If you are a man with advanced lung cancer and are sexually active, researchers want to learn about your experiences and test results.
RomeAges 18–75 - NCT04116541RecruitingPhase 2
Targeted therapy for advanced cancer based on tumor genetics
This trial tests different targeted therapies based on the unique genetic changes in your tumor. It is for people with advanced or metastatic cancer who have exhausted standard options and whose tumor has specific genetic markers matched to one of the study drugs.
AngersAges 18 years+ - NCT05722886RecruitingPhase 2/Phase 3
Screening trial for rare cancer gene changes in existing medicines
This trial checks whether existing cancer medicines can help people whose tumors have specific “gene changes” (mutations). You may be assigned to a treatment arm that matches your tumor’s gene results after fresh biopsy and blood testing.
BelfastAges Any age - NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+
What Alectinib is being studied for
Conditions with recruiting Alectinib studies.
Common questions
- Are there clinical trials studying Alectinib?
- Yes. Clin2 currently lists 20 recruiting studies that include Alectinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Alectinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Alectinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Alectinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.